

## **Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic.**

Amitava Banerjee<sup>1,2,3,4</sup>, Suliang Chen<sup>1,2</sup>, Laura Pasea<sup>1,2</sup>, Alvina G. Lai<sup>1,2</sup>, Michail Katsoulis<sup>1,2</sup>, Spiros Denaxas<sup>1,2</sup>, Vahe Nafilyan<sup>5</sup>, Bryan Williams<sup>4,6,7</sup>, Wai Keong Wong<sup>1,4</sup>, Ameet Bakhai<sup>8</sup>, Kamlesh Khunti<sup>9</sup>, Deenan Pillay<sup>10</sup>, Mahdad Noursadeghi<sup>4,10</sup>, Honghan Wu<sup>1,2,11</sup>, Nilesh Pareek<sup>12</sup>, Daniel Bromage<sup>12, 13</sup>, Theresa A. McDonagh<sup>12, 13</sup>, Jonathan Byrne<sup>12</sup>, James T.H. Teo<sup>12</sup>, Ajay M Shah<sup>12,13</sup>, Ben Humberstone<sup>5</sup>, Liang V. Tang<sup>14</sup>, Anoop S. V. Shah<sup>15</sup>, Andrea Rubboli<sup>16</sup>, Yutao Guo<sup>17</sup>, Yu Hu<sup>14</sup>, Cathie L. M. Sudlow<sup>2, 18, 19</sup>, Gregory Y. H. Lip<sup>20\*</sup>, Harry Hemingway<sup>1,2\*</sup>

\**joint senior author*

<sup>1</sup>Institute of Health Informatics, University College London, London, UK

<sup>2</sup>Health Data Research UK, University College London, London, UK.

<sup>3</sup>Barts Health NHS Trust, London, UK

<sup>4</sup>University College London Hospitals NHS Trust, London, UK

<sup>5</sup>Office of National Statistics, London, UK.

<sup>6</sup>Institute of Cardiovascular Science, University College London (UCL), London, UK.

<sup>7</sup>University College London Hospitals NIHR Biomedical Research Centre, London, UK

<sup>8</sup>Royal Free Hospitals NHS Trust, London

<sup>9</sup>Diabetes Research Centre, University of Leicester.

<sup>10</sup>Division of Infection and Immunity, University College London, London, UK.

<sup>11</sup> School of Computer and Software, Nanjing University of Information Science and Technology, Nanjing, China.

<sup>12</sup>King's College Hospital NHS Foundation Trust, London.

<sup>13</sup>Kings College London British Heart Foundation Centre, School of Cardiovascular Medicine & Sciences, London.

<sup>14</sup>Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

<sup>15</sup>Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, Scotland

<sup>16</sup>Division of Cardiology, Ospedale S. Maria delle Croci, Ravenna, Italy.

<sup>17</sup>PLA General Hospital, Beijing, China.

<sup>18</sup>Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK.

<sup>19</sup>BHF Data Science Centre, Health Data Research UK

<sup>20</sup>Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

### **Correspondence:**

Amitava Banerjee [ami.banerjee@ucl.ac.uk](mailto:ami.banerjee@ucl.ac.uk)

Abstract word count: 250

**Background:** Cardiovascular diseases(CVD) increase mortality risk from coronavirus infection(COVID-19), but there are concerns that the pandemic has affected supply and demand of acute cardiovascular care. We estimated excess mortality in specific CVDs, both “direct”, through infection, and “indirect”, through changes in healthcare.

**Methods:** We used population-based electronic health records from 3,862,012 individuals in England to estimate pre- and post-COVID-19 mortality risk(“direct” effect) for people with incident and prevalent CVD. We incorporated: (i)pre-COVID-19 risk by age, sex and comorbidities, (ii)estimated population COVID-19 prevalence, and (iii)estimated relative impact of COVID-19 on mortality(relative risk, RR: 1.5, 2.0 and 3.0). For “indirect” effects, we analysed weekly mortality and emergency department data for England/Wales and monthly hospital data from England(n=2), China(n=5) and Italy(n=1) for CVD referral, diagnosis and treatment until 1 May 2020.

**Findings:** CVD service activity decreased by 60-100% compared with pre-pandemic levels in eight hospitals across China, Italy and England during the pandemic. In China, activity remained below pre-COVID-19 levels for 2-3 months even after easing lockdown, and is still reduced in Italy and England. Mortality data suggest indirect effects on CVD will be delayed rather than contemporaneous(peak RR 1.4). For total CVD(incident and prevalent), at 10% population COVID-19 rate, we estimated direct impact of 31,205 and 62,410 excess deaths in England at RR 1.5 and 2.0 respectively, and indirect effect of 49932 to 99865 excess deaths.

**Interpretation:** Supply and demand for CVD services have dramatically reduced across countries with potential for substantial, but avoidable, excess mortality during and after the COVID-19 pandemic.

**Funding:** NIHR, HDR UK, Astra Zeneca

## Introduction

Coronavirus disease 2019(COVID-19) has had unplanned consequences for non-COVID-19 health services. We described reductions in urgent cancer referrals and chemotherapy compared to pre-COVID-19 levels<sup>1</sup>. Decreases in presentation and treatment of myocardial infarction(MI)<sup>2-4</sup> in Italy and the USA suggest effects on care, but services have not been studied across specific CVDs, countries or different phases of the pandemic.

Early reports from Wuhan, China, demonstrated high prevalence of and mortality from COVID-19 in individuals with CVD; confirmed across countries, particularly with coronary heart disease(CHD) and heart failure(HF)<sup>5-8</sup>. UK government policy for “physical distancing” in high-risk subgroups for COVID-19, announced on 16 March 2020, included CVD, especially HF<sup>9</sup>. On 22 March 2020, a further 1.5 million people in England(with ‘extremely vulnerable’ conditions) were recommended at least 12 weeks of ‘shielding’<sup>10</sup>, excluding those with CVD, prior to UK lockdown on 23 March<sup>11</sup>. Better understanding of pre- and post-COVID-19 mortality risk across specific CVDs may help decisions and policies regarding physical isolation.

Therefore, effects of COVID-19 on individuals and health systems are: (i)*direct* due to infection, and (ii)*indirect* due to unprecedented system strain and associated behaviour changes<sup>12</sup>. Those with CVD, carrying the greatest burden of global morbidity and mortality<sup>13</sup>, are likely to be particularly affected. Beyond direct effects, systematic examination of recent and longer-term trends for CVD services may help in planning the timing and nature of exit from lockdown and strategies for any subsequent infection peaks. Moreover, reductions in rates of referral, diagnosis, and treatment, may have fatal long-term consequences, caused by “supply”(e.g. lower healthcare availability) and/or “demand”(e.g. delayed presentation), but have not been investigated. Electronic health records(EHR) have been used in studies across different specific CVDs<sup>14</sup>, and enable novel insights regarding direct and indirect COVID-19-related excess deaths, across incident and prevalent CVD, and the spectrum of care.

**Objective:** We used: (i)national mortality data for England and Wales to investigate trends in non-COVID-19 and CVD excess deaths; (ii)routine data from hospitals in England, Italy and China to assess indirect effects on services for referral, diagnosis and treatment of CVD during the pandemic; and (iii)population-based EHR in England to investigate pre-COVID-19 mortality by underlying risk factors and excess mortality during the COVID-19 pandemic.

## Methods

### Data sources and study population

To estimate pre-COVID-19 incidence and mortality in individuals with CVD and comorbidities, we used EHR across primary care(Clinical Practice Research Datalink, CPRD-GOLD), hospital care(Hospital Episodes Statistics, HES), and death registry(Office of National Statistics, ONS) with prospective recording and follow-up; linked by CPRD and NHS Digital using unique healthcare identifiers<sup>15</sup>. Over 99% of England's population is registered with general practice(GP). CPRD is representative by socio-demography, ethnicity and overall mortality<sup>16</sup>. Eligible individuals were aged  $\geq 30$  years, registered with a GP between 1 January 1997 and 1 January 2017 with  $\geq 1$  year of follow-up. Study entry was 1 year following latest GP registration for each individual, to more completely capture past medical history.

### Open-access electronic health record phenotypes

We defined non-fatal(alive for  $\geq 30$  days post-diagnosis) CVD using 16 previously validated CALIBER phenotypes: stable angina, unstable angina, MI, CHD unspecified, HF, cardiac arrest, transient ischaemic attack(TIA), ischaemic stroke, stroke unspecified, intracerebral haemorrhage, subarachnoid haemorrhage, peripheral arterial disease(PAD), atrial fibrillation(AF), abdominal aortic aneurysm(AAA), DVT and pulmonary embolism(PE), as per prior studies<sup>14-16</sup>. We included DVT and PE due to clinical importance of venous thromboembolism in COVID-19<sup>17</sup>. Incident and prevalent CVD were defined by first CVD record in the study period with no prior CVD history, and first prior CVD history, respectively. Validated phenotype definitions of diseases and COVID-19-relevant conditions(available at <https://caliberresearch.org/portal>)<sup>14-16</sup> were generated from hospital and primary care information recorded in primary care, using Read clinical terminology(version 2).

We defined 15 comorbidities or comorbidity clusters involving 40 individual conditions associated with poor COVID-19 outcomes by UK government guidance<sup>9,10</sup>. Further details are provided in **Supplementary Methods**. Multimorbidity was co-occurrence of  $\geq 2$  of these conditions<sup>18</sup>.

### Weekly/monthly information on CVD care and mortality

We obtained: (i)weekly cause-specific mortality data for England and Wales from ONS<sup>19</sup> and cardiac-related attendance data from the Emergency Department(ED) Syndromic Surveillance System for England<sup>20</sup>; (ii)monthly referral, diagnosis and treatment data for

CVD in two UK hospitals(University College London NHS Trust, and King's College Hospital London NHS Foundation Trust); and (iii)hospital data in China(n=5; Wuhan Union Hospital, Zaoyang First Hospital, Xiangyang First Hospital, Xiantao People's Hospital, Tianmen First Hospital) and Italy(n=1; Ospedale Santa Maria delle Croci, Ravenna). For all data, weekly or monthly relative risks(RRs) were calculated compared with the pre-lockdown data(from 3 January). Further details of data and RR calculations are given in the **Supplementary Methods**.

#### Estimating incidence rates and 1-year mortality

We estimated incidence rates per 100,000 person-years and pre-COVID-19 1-year mortality risk for incident and prevalent CVD using Kaplan-Meier analyses stratified by specific CVD and number of (non-CVD) comorbidities(0, 1, 2 and 3+), scaling up from CALIBER(3.8 million individuals) to the whole population of England aged 30+, consisting of 35,407,313 individuals(using 2018 estimates of overall population size and mortality<sup>21</sup>).

#### Estimating 1-year direct and indirect excess deaths

Excess deaths were considered as direct(due or with COVID-19 infection) or indirect(due to changes in health services). *Direct excess deaths* were estimated by applying RRs of 1.2, 1.5, 2 and 3, based on published hazard ratios for CVD and COVID-19 deaths<sup>8,22,23</sup>, in the absence of cohort studies of clinical cohorts of CVD patients investigating all-cause mortality in those with and without infection. We modelled 10% infection rate based on recent COVID-19 seroprevalence estimates<sup>24-25</sup>. Although infection rate will change depending on pandemic phase, we assumed infection rate over 1 year in line with the first wave.

Given service changes in CVD observed across countries<sup>2-4</sup>, to capture *direct* and *indirect* excess deaths, we modelled in addition to the 10% infected, 40% and 80% affected rates, where 30% and 70% of the population respectively would be un-infected but affected at corresponding RRs. Based on RRs from ONS data(peak RR 1.14 for excess CVD deaths and 1.29 for excess non-COVID-19 deaths; **Figure 2**) and likely longer-term effects on CVD mortality, we estimated direct and indirect excess deaths together by applying RR 1.2 to 40% and 80% of the population. Thus, we provide *low*(infection rate 10% and no indirect effect at RR 1.5, 2.0 and 3.0), *medium*(infection rate 10% and 30% indirectly affected at RR 1.2) and *high* estimates(infection rate 10% and 70% indirectly affected at RR 1.2) of excess deaths. We projected excess death estimates to the whole English population, we used the 2018 population estimate of 35,407,313 individuals aged  $\geq 30$ <sup>21</sup>. All analyses were performed using R(version 3.4.3).

## Results

### Monthly hospital data across countries

In China (both Wuhan and other hospitals) and Italy, activity(referral, diagnosis and treatment) was significantly reduced compared with pre-COVID levels. In Wuhan, there was 83.4% reduction in referral, 92% in diagnosis and 99% in treatment levels of MI by the 1 February, a month after the outbreak started. Corresponding decreases were 92%, 97% and 87% for stroke, 83%, 93% and 98% for HF, and 83%, 95% and 94% for AF. Tianmen and Xiantao demonstrated equivalent decreases across all four disease services. Although decreases were relatively less in Zaoyang and Xiangtang, there were 40-80% reductions across services, except for diagnosis of MI which increased in Zaoyang between January and March.

Even after easing and stopping of lockdown, Wuhan reported 50-100% decreases in services for MI, stroke, HF and AF. In other Chinese hospitals, activity had mostly returned to pre-COVID levels by April 2020. Recovery of activity began to occur during the lockdown period and differed across Chinese hospitals, suggesting possible differences in infection rates, patient presentation and behaviour, clinician behaviour and COVID-19-related system strain. In Italy, decreases ranged from 45% for stroke treatment to 94% for HF treatment and 100% for AF diagnosis. In England, there was reduced activity across CVDs during the pandemic. Services in Italy and England had not reached pre-COVID levels even by the easing of lockdown. Across countries, referral rates for all diseases and treatment of MI were particularly affected and declines in activity occurred before the peak of cases or deaths(**Figure 1**).

### Weekly national mortality data and emergency attendance data

Non-COVID-19 and CVD-related deaths in England and Wales increased in the same chronology as total(including COVID-19) deaths until mid-May 2020(compared with the same week over the last 5 years). The peak observed RR for CVD deaths was in the week ending 24 April(1850 vs 1626 deaths, RR 1.14) and the lowest in the week ending 8 May 2020(1318 vs 1487 deaths, RR 0.89). The same trend was present regardless of whether the RR was calculated compared to the average of previous years, or pre-COVID-19(3 January 2020). Between 6 and 27 March, cardiac ED attendances decreased in England(minimum RR 0.57) and were had not fully recovered on 15 May, which was after easing of lockdown(**Figure 2**).

### Incidence, prevalence and pre-COVID-19 mortality for CVD

Of 3,862,012 individuals in our English cohort, 538,037 had incident CVD and 580,437 had prevalent CVD. Age-adjusted incidence rates(per 100,000 population) were highest for AF(330), CHD(261), HF(168), stable angina(140), and DVT(139)(**Figure S1**). For incident CVDs, 1-mortality rates varied by specific CVD: 58.4% for cardiac arrest, 42.1% for intracerebral haemorrhage, 30.3% for HF, 20.1% for MI, 12.1% for CHD, 4.8% for stable angina,. Absolute 1-year mortality was highest for AF(234,778), HF(173,955), CHD(114,383) and stroke(63,276). Mortality rates were relatively lower for prevalent CVDs(**Figure S2**).

#### Comorbidities in individuals with CVD

Across incident and prevalent CVDs, prevalence of 0, 1, 2 and 3+ co-morbidities was 26.2% and 27.1%, 33.2% and 36.3%, 21.9% and 20.5%, 18.6% and 16.2% respectively. Across CVDs, hypertension, CKD, cancer, chronic obstructive pulmonary disease(COPD) and diabetes were commonest(**Supplementary Table 1, Figure S3**). Comorbidity profiles were similar in those with prevalent CVD(**Figure S4**). Multimorbidity was associated with increased 1-year mortality, e.g. in incident AF, 1-year mortality was 31% vs 9% in men and 34% vs 16% in women for  $\geq 3$  vs 0 conditions. One-year mortality risks were  $>50\%$  in those with incident cardiac arrest or intracerebral haemorrhage and  $\geq 3$  conditions(**Figures 3B** and **S5B**).

#### Estimates for direct and indirect excess 1-year COVID-19-related deaths

For incident CVD, at 10% infection rate, there would be 5067, 10,135 and 20,269 excess deaths at RR 1.5, 2.0 and 3.0 respectively. At 40% and 80% infection rates, we estimated 8112 and 16225 excess deaths at RR 1.2 (**Figure 4A**).

For prevalent CVD, at 10% infection rate, there would be 26,138, 52,275 and 104,550 excess deaths at RR 1.5, 2.0 and 3.0 respectively. At 40% and 80% infection rates, we estimated 41820 and 83640 excess deaths at RR 1.2(**Figure 5A**).

For total CVD(incident and prevalent combined), at 10% infection rate, we estimated a direct effect of 31,205, 62,410, and 124, 819 excess deaths at RR, 1.5, 2.0 and 3.0 respectively. For total CVD, we estimate an indirect effect of 49932 to 99865 excess deaths using 40% and 80% infection rate estimates.

For incident CVD, at 10% COVID-19 rate, we estimated 2508 vs 1068, 5016 vs 2136 and 10033 vs 4272 excess deaths in multimorbidity compared with no comorbidities at RR 1.5, 2.0 and 3.0 respectively. At 40% COVID-19 rate, we estimated 4013 vs 1709 excess deaths; and at 80% COVID-19 rate, we estimated 8026 vs 3417 excess deaths in multimorbidity

compared with no comorbidities at corresponding RRs(**Figure 4B**). Among those with prevalent CVDs, we estimated higher excess deaths at 1 year than for incident CVDs with similar associations with number of comorbidities(**Figure 5B**).

## Discussion

This first analysis from large-scale population-based EHR across 16 specific CVDs and multimorbidity in the COVID-19 context has four findings. First, profound disruption of CVD services across referral, diagnosis and treatment(seen in UK, Italy and China) may contribute to excess deaths. Second, there are high rates of “high-risk” and “extremely vulnerable” conditions among people with CVD, often in combination, varying by specific CVD. Third, we predict significant excess deaths in individuals with CVD, over a 1-year time horizon partly because indirect effects may be delayed. Fourth, excess deaths in prevalent and incident CVD, by direct and indirect effects, suggest that access to acute and chronic CVD care should be prioritised during future pandemic waves.

Professional organisations quickly produced evidence-based CVD management guidelines in the COVID-19 context<sup>26</sup>. Our analysis highlights the pandemic’s real and potential impact on CVD healthcare provision in different countries at different stages in their responses. At peak, almost all CVD healthcare activity collapsed in Wuhan. Although Italy and the UK were affected later, CVD services were, and still are, compromised in pre-lockdown and lockdown phases. Changes in CVD excess deaths have not yet been observed in ONS data, suggesting that indirect effects may manifest over at least a year, rather than contemporaneously with activity reductions observed across countries. Overall, these data emphasise indirect effects of COVID-19, helping to quantify and model true “relative impact”, and relative contributions of pandemic versus lockdown on CVD services. We believe countries should monitor near real-time service activity, and COVID-19 and non-COVID-19 deaths<sup>27</sup> over the coming year to understand and mitigate excess deaths in individuals with CVD, especially in those countries still at earlier phases, such as Brazil.

There is debate about which conditions should be on “high-risk” and “extremely vulnerable” lists of conditions for physical isolation policies, which should include some CVDs and combinations of comorbidities, based on our risk estimates and COVID-death data to-date<sup>6,12</sup>. CVD is known to have high prevalence, incidence and mortality, varying by arterial territory. We now show that AF, CHD, HF, stable angina, and DVT have the highest pre-COVID-19 incidence rates. Prognosis varies by incident versus prevalent disease, specific CVD and number and combination of comorbidities, highlighting need for individualised risk

prediction across CVD. On a different note, our findings also bring into question the rationale for looking at composite endpoints such as “MACE”(major adverse cardiovascular events) in trials and other studies due to highly variable risk across specific CVD<sup>28</sup>.

In individuals with CVD at 10% population infection rate, there would be 50,937 excess deaths at RR 1.5, with higher rates at higher infection rates. An earlier lockdown, as in New Zealand or the Indian state of Kerala, minimises overall deaths. Conversely, in countries such as the UK and USA, delayed lockdown may exacerbate direct and indirect effects of COVID-19, supported by rising non-COVID-19 deaths in ONS data. COVID-19 and non-COVID-19 deaths can be avoided by: (i) acting early and reducing infection rates by widespread testing, stringent physical isolation and suppression policies, and (ii) focusing on the preventable CVD burden. For example, HF, MI, ischaemic stroke and AF are prevalent conditions with highest mortality rates; all with evidence-based therapies. The same is true for common CVD comorbidities, which often occur in clusters: hypertension, CKD, cancer, COPD and diabetes, underlining importance of integrated CVD and risk factor management pre- and post-COVID-19.

Our findings may have implications for which aspects of health services(acute vs chronic, treatment vs prevention, across specific CVDs) require attention at different pandemic phases. Demand for NCD care is documented in humanitarian emergencies<sup>29</sup>, but NCD surveillance is absent in pandemic preparedness, planning and responses, particularly in low-middle income countries<sup>13</sup>, where our findings will be magnified. The learning health system concept<sup>30</sup>, where near real-time data inform science, evidence and care, has not been used optimally during the COVID-19 pandemic, but our CVD referral, diagnosis and treatment data show that data need not be complex.

### ***Strengths and limitations***

Our study uses large-scale, nationally representative EHR with validated definitions across a comprehensive list of specific CVDs and comorbidities. We present real-time service data from three countries. There are several limitations. In the UK, our study population was 5% of the overall population. We do not have country-level data outside the UK. Our analyses of risk and excess deaths use retrospective EHR data. Our model assumes static infection rate and RR and do not include changes over time. We used service data from limited hospitals and only UK(ONS) administrative data was available. We do not report primary care or community level data regarding CVD services. We modelled using limited comorbidities and simple multimorbidity counts, and did not study impact of ethnicity. We assumed the same effect across all specific CVDs.

## **Conclusion**

There is a substantial avoidable burden of excess mortality in people with CVD during the COVID-19 pandemic. Excess CVD deaths can be reduced in more integrated approaches, focused on reducing COVID-19 infection rates, as well as managing CVD and comorbidities.

### **Contributor and guarantor information:**

Research question: AB, GYHL, HH

Funding: AB, HH

Study design and analysis plan: AB, SC, AL, LP, HH

Preparation of data, including electronic health record phenotyping in the CALIBER open portal: SC, LP, SD

Provision of monthly hospital data: JT, AS, DB, TM, NP, JM, WKW, BW, AR, LVT, YG, YT, GYHL.

Provision of weekly cause-specific mortality data: VN, BH

Provision of EDSS data: MK

Statistical analysis: SC, LP, AB

Drafting initial versions of manuscript: AB

Drafting final versions of manuscript: AB, GYHL, HH

Critical review of early and final versions of manuscript: All authors

The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. AB and HH are the guarantors.

## **Ethical approval**

This study was approved by the Independent Scientific Advisory Committee of the CPRD(20\_074R) under Section 251(NHS Social Care Act 2006) of the UK Medicines and Healthcare products Regulatory Agency. Hospital data was obtained with approval of the relevant hospital institutional review boards.

## **Funding acknowledgements**

AB has received research funding from NIHR, UKRI, British Medical Association and Astra Zeneca. BW and HH are funded by the National Institute for Health Research (NIHR)

University College London Hospitals Biomedical Research Centre. HH is supported by Health Data Research UK (HDR-UK; grant no LOND1 ), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, and Wellcome Trust. AB, SC, SD, HH is also supported by the BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 joint undertaking under grant agreement no 116074. This joint undertaking receives support from the EU's Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations. AMS is supported by the British Heart Foundation (CH/1999001/11735), the NIHR Biomedical Research Centre at Guy's & St Thomas' NHS Foundation Trust and King's College London (IS-BRC-1215-20006), and the Fondation Leducq. KK is supported by NIHR ARC East Midlands. BW is supported by the NIHR University College London Hospitals Biomedical Research Centre. HW is supported by Medical Research Council and Health Data Research UK Grant (MR/S004149/1), Industrial Strategy Challenge Grant (MC\_PC\_18029) and Wellcome Institutional Translation Partnership Award (P111054). MN is supported by a Wellcome Trust Investigator in Science award (207511/Z/17/Z). DB is supported by the NIHR (CL-2016-17-001).

## **Research in Context**

### **Evidence before this study**

Coronavirus disease 2019 (COVID-19) can cause excess deaths through direct (due to infection) and indirect effects. We searched PubMed, medRxiv, bioRxiv, arXiv, and Wellcome Open Research for peer-reviewed articles, preprints, and research reports on mortality and cardiovascular disease (CVD) in (COVID-19), using the search terms “coronavirus”, “COVID-19”, “cardiovascular disease” and similar terms, and “mortality”, up to May 31, 2020. We found no prior studies of excess deaths in those with cardiovascular disease and the COVID-19 pandemic. Health services for myocardial infarction appear to have decreased in some countries, but services for CVD have not been studied across specific CVDs, countries or different phases of the pandemic. Such data will enable better prediction of the direct and indirect effects of COVID-19 and planning for health system responses.

### **Added value of this study**

Comparing hospital data from the UK, Italy and China, we show a profound disruption of CVD services across referral, diagnosis and treatment which may contribute to excess deaths. Using a published model, we estimated the excess COVID-19-related mortality in individuals with CVD by incorporating population infection rate in different scenarios, differing degrees of impact of COVID-19 on health systems, and prevalence of underlying conditions. As well as high rates of multimorbidity, we predict high excess deaths in individuals with CVD, over a 1-year time horizon partly because indirect effects may be delayed.

### **Implications of all the available evidence**

Our findings regarding excess deaths in prevalent and incident CVD, by direct and indirect effects, suggest that access to acute and chronic CVD care should be prioritised during future pandemic waves, as well as efforts and strategies to minimise infection rate in the population.

## References

1. Lai AG, Pasea L, Banerjee A, Denaxas S, Katsoulis M, Chang WH, Williams B, Pillay D, Noursadeghi M, Swanton C, Linch D, Hughes D, Forster MD, Johnson P, Turnbull C, DATA-CAN, Cooper M, Jones M, Pritchard-Jones K, Sullivan R, Lawler M, Hall G, Davie C, Hemingway H. Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency. 2020. Preprint 29/4/2020. [https://www.researchgate.net/publication/340984562\\_Estimating\\_excess\\_mortality\\_in\\_people\\_with\\_cancer\\_and\\_multimorbidity\\_in\\_the\\_COVID-19\\_emergency](https://www.researchgate.net/publication/340984562_Estimating_excess_mortality_in_people_with_cancer_and_multimorbidity_in_the_COVID-19_emergency)
2. De Rosa S, Spaccarotella C, Basso C, Calabrò MP, Curcio A, Filardi PP, Mancone M, Mercuro G, Muscoli S, Nodari S, Pedrinelli R, Sinagra G, Indolfi C, Società Italiana di Cardiologia and the CCU Academy investigators group. Reduction of Hospitalizations for Myocardial Infarction in Italy in the COVID-19 Era. *Eur Heart J*. 2020 May 15;ehaa409. doi: 10.1093/eurheartj/ehaa409. Online ahead of print.
3. De Filippo O, D'Ascenzo F, Angelini F, Bocchino PP, Conrotto F, Saglietto A, Secco GG, Campo G, Gallone G, Verardi R, Gaido L, Iannaccone M, Galvani M, Ugo F, Barbero U, Infantino V, Olivotti L, Mennuni M, Gili S, Infusino F, Vercellino M, Zucchetti O, Casella G, Giammaria M, Boccuzzi G, Tolomeo P, Doronzo B, Senatore G, Marra WG, Rognoni A, Trabattoni D, Franchin L, Borin A, Bruno F, Galluzzo A, Gambino A, Nicolino A, Giachet AT, Sardella G, Fedele F, Monticone S, Montefusco A, Omedè P, Pennone M, Patti G, Mancone M, De Ferrari GM. Reduced Rate of Hospital Admissions for ACS During Covid-19 Outbreak in Northern Italy. *N Engl J Med*. 2020 Apr 28;NEJMc2009166. doi: 10.1056/NEJMc2009166.
4. Bhatt AS, Moscone A, McElrath EE, Varshney AS, Claggett BL, Bhatt DL, Januzzi JL, Butler J, Adler DS, Solomon SD and Vaduganathan M. Declines in Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic: A Multicenter Tertiary Care Experience. *J Am Coll Cardiol*. 2020. DOI: 10.1016/j.jacc.2020.05.038. Online ahead of print.
5. Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, Prill M, Chai SJ, Kirley PD, Alden NB, Kawasaki B, Yousey-Hindes K, Niccolai L, Anderson EJ, Openo KP, Weigel A, Monroe ML, Ryan P, Henderson J, Kim S, Como-Sabetti K, Lynfield R, Sosin D, Torres S, Muse A, Bennett NM, Billing L, Sutton M, West N, Schaffner W, Talbot HK, Aquino C, George A, Budd A, Brammer L, Langley G, Hall AJ, Fry A. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Apr 17;69(15):458-464
6. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; and the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*. 2020 Apr 22. doi: 10.1001/jama.2020.6775.
7. ICNARC report on COVID-19 in critical care. 24 April 2020 <https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports> (accessed 29 April 2020)
8. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. *Int J Infect Dis*. 2020 Mar 12. pii: S1201-9712(20)30136-3. doi: 10.1016/j.ijid.2020.03.017
9. Public Health England. Guidance on social distancing for everyone in the UK and protecting older people and vulnerable adults. 16 March 2020. <https://www.gov.uk/government/publications/covid-19-guidance-on-social-distancing-and-for-vulnerable-people/guidance-on-social-distancing-for-everyone-in-the-uk-and-protecting-older-people-and-vulnerable-adults> (accessed 29 April 2020)
10. UK Government. <https://www.gov.uk/government/news/major-new-measures-to-protect-people-at-highest-risk-from-coronavirus> (accessed 29 April 2020)

11. UK Government. PM address to the nation on coronavirus: 23 March 2020. <https://www.gov.uk/government/speeches/pm-address-to-the-nation-on-coronavirus-23-march-2020> (accessed 29 April 2020)
12. Banerjee A, Pasea L, Harris S, Gonzalez-Izquierdo A, Torralbo A, Shallcross L, Noursadeghi M, Pillay D, Sebire N, Holmes C, Pagel C, Wong WK, Langenberg C, Williams B, Denaxas S, Hemingway H. Estimating excess 1-year mortality from COVID-19 according to underlying conditions and age in England: a rapid analysis using NHS health records in 3.8 million adults. *Lancet* May 12. doi: 10.1016/S0140-6736(20)30854-0.
13. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1789-1858.
14. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. *Lancet Diabetes Endocrinol*. 2015;3(2):105-13.
15. Denaxas S, Gonzalez-Izquierdo A, Direk K, Fitzpatrick NK, Fatemifar G, Banerjee A, Dobson RJB, Howe LJ, Kuan V, Lumbers RT, Pasea L, Patel RS, Shah AD, Hingorani AD, Sudlow C, Hemingway H. UK phenomics platform for developing and validating electronic health record phenotypes: CALIBER. *J Am Med Inform Assoc*. 2019;26(12):1545-59.
16. George J, Mathur R, Shah AD, et al. Ethnicity and the first diagnosis of a wide range of cardiovascular diseases: associations in a linked electronic health record cohort of 1 million patients. *PLoS One* 2017; 12 6: e0178945.
17. Zhai Z, Li C, Chen Y, Gerotziafas G, Zhang Z, Wan J, Liu P, Elalamy I, Wang C; Prevention Treatment of VTE Associated with COVID-19 Infection Consensus Statement Group. Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines. *Thromb Haemost*. 2020 Apr 21. doi: 10.1055/s-0040-1710019.
18. Hurst JR, Dickhaus J, Maulik PK, Miranda JJ, Pastakia SD, Soriano JB, et al. Global Alliance for Chronic Disease researchers' statement on multimorbidity. *Lancet Glob Health*. 2018;6(12):e1270-e1.
19. Office of National Statistics. Deaths involving COVID-19, England and Wales: deaths occurring in April 2020. (Accessed 21/5/20) <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvingcovid19englandandwales/deathsoccurringinapril2020>
20. Emergency Department Syndromic Surveillance System: England. 27 May 2020. [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/887777/EDSSSBulletin2020wk21.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/887777/EDSSSBulletin2020wk21.pdf) (Accessed 2 June 2020)
21. Office for National Statistics. Deaths by single year of age tables, UK. <https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/deathregistrationssummarytablesenglandandwalesdeathsbyingleyearofagetables> Date: Jan 17, 2020. Date accessed: April 16, 2020
22. Chen R, Liang W, Jiang M, Guan W, Zhan C, Wang T, Tang C, Sang L, Liu J, Ni Z, Hu Y, Liu L, Shan H, Lei C, Peng Y, Wei L, Liu Y, Hu Y, Peng P, Wang J, Liu J, Chen Z, Li G, Zheng Z, Qiu S, Luo J, Ye C, Zhu S, Liu X, Cheng L, Ye F, Zheng J, Zhang N, Li Y, He J, Li S, Zhong N; Medical Treatment Expert Group for COVID-19. Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China. *Chest*. 2020 Apr 15:S0012-3692(20)30710-8. doi: 10.1016/j.chest.2020.04.010. Online ahead of print.
23. The OpenSAFELY Collaborative; Williamson E, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald, HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong

- A, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans S, Smeeth L, Goldacre B. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. Medrxiv. 7 May 2020.  
<https://www.medrxiv.org/content/10.1101/2020.05.06.20092999v1.full.pdf>
24. Office of National Statistics. Coronavirus (COVID-19) Infection Survey. <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/coronaviruscovid19infectionsurveydata> (Accessed 1 June 2020)
  25. Valenti L, Bergna A, Pelusi S, Facciotti F, Lai A, Tarkowski M, Berzuini A, Caprioli F, Santoro L, Baselli G, Ventura CD, Erba E, Bosari S, Galli M, Zehender G, Prati D. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak. May 31 2020. (Accessed 1 June 2020)  
<https://www.medrxiv.org/content/10.1101/2020.05.11.20098442v1>
  26. European Society of Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. 21 April 2020.  
<https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance>
  27. Figueroa J, Brennan P, Theodoratou E, Poon M, Purshouse K, Din F, Jin K, Mesa-Eguiagaray I, Dunlop MG, Hall PS, Cameron D, Wild S, Sudlow CLM. Trends in excess cancer and cardiovascular deaths in Scotland during the COVID-19 pandemic 30 December 2019 to 20 April 2020. medrxiv. 2020. Preprint. 6 May 2020.  
<https://www.medrxiv.org/content/10.1101/2020.05.02.20086231v1>
  28. Home P. Cardiovascular outcome trials of glucose-lowering medications: an update. *Diabetologia*. 2019 Mar;62(3):357-369. doi: 10.1007/s00125-018-4801-1.
  29. Demaio A, Jamieson J, Horn R, de Courten M, Tellier S. Non-communicable diseases in emergencies: a call to action. *PLoS Curr*. 2013 Sep 6;5.
  30. Banerjee A, Drumright LN, Mitchell ARJ. Can the NHS be a learning healthcare system in the age of digital technology? *BMJ Evid Based Med*. 2018 Oct;23(5):161-165.

## Figures and Tables

Figure 1. Hospital activity before and during the COVID-19 pandemic for referral, diagnosis and treatment of cardiovascular disease in China, Italy and England.

Figure 2. Weekly national data for excess total, non-COVID and cardiovascular deaths in England and Wales, and emergency department cardiac attendances for England.

Figure 3: COVID-19 relevant comorbidities in incident cardiovascular diseases in England: (A) Proportion of individuals with 0, 1, 2 and 3+ comorbidities by specific CVD. (B) 1-year mortality in individuals with 0, 1, 2 and 3+ comorbidities by specific CVD.

Figure 4: Estimated number excess deaths at 1 year due to COVID-19 pandemic by CVD type for: (A) incident cases; and (B) number of comorbidities for incident cases

Figure 5: Estimated number excess deaths at 1 year due to COVID-19 pandemic by CVD type for: (A) prevalent cases; and (B) number of comorbidities for prevalent cases.

Figure 1: Hospital activity before and during the COVID-19 pandemic for referral, diagnosis and treatment of cardiovascular disease in China, Italy and England.

---

Figure 2. Weekly national data for excess total, non-COVID and cardiovascular deaths in England and Wales, and emergency department cardiac attendances for England: relative risks.




Figure 3: COVID-19 relevant comorbidities in incident cardiovascular diseases in England: (A) Proportion of individuals with 0, 1, 2 and 3+ comorbidities by specific CVD. (B) 1-year mortality in individuals with 0, 1, 2 and 3+ comorbidities by specific CVD.




Figure 4: Estimated number excess deaths at 1 year due to COVID-19 pandemic by CVD type for: (A) incident cases; and (B) number of comorbidities for incident cases.




Figure 5: Estimated number excess deaths at 1 year due to COVID-19 pandemic by CVD type for: (A) prevalent cases; and (B) number of comorbidities for prevalent cases


A.

CVD Type	Population infection rate in the COVID-19 pandemic											
	10%			40%			80%			Relative Risk		
	1.2	1.5	2	3	1.2	1.5	2	3	1.2	1.5	2	3
Heart failure	1696	4241	8481	16962	6785	16962	33925	67850	13570	33925	67850	135689
Atrial fibrillation	1487	3716	7433	14866	5946	14866	29731	59462	11892	29731	59462	118924
Stable angina	1377	3442	6884	13768	5507	13768	27537	55073	11015	27537	55073	110146
Coronary heart disease	1339	3347	6695	13389	5356	13389	26778	53557	10711	26778	53557	107113
Stroke not otherwise specified	918	2294	4588	9175	3670	9175	18351	36701	7340	18351	36701	73402
Myocardial infarction	855	2138	4277	8554	3422	8554	17108	34216	6843	17108	34216	68431
Transient ischaemic attack	736	1840	3681	7362	2945	7362	14723	29446	5889	14723	29446	58893
Peripheral arterial disease	617	1543	3086	6171	2469	6171	12343	24685	4937	12343	24685	49371
Unstable angina	336	840	1680	3360	1344	3360	6720	13440	2688	6720	13440	26881
Ischaemic stroke	315	788	1576	3151	1260	3151	6302	12604	2521	6302	12604	25209
Deep vein thrombosis	282	705	1410	2820	1128	2820	5640	11281	2256	5640	11281	22562
Pulmonary embolism	163	408	815	1631	652	1631	3261	6522	1304	3261	6522	13045
Abdominal aortic aneurysm	159	397	794	1588	635	1588	3176	6351	1270	3176	6351	12703
Intracerebral haemorrhage	99	246	493	986	394	986	1972	3944	789	1972	3944	7887
Cardiac arrest	44	110	221	442	177	442	883	1766	353	883	1766	3533
Subarachnoid haemorrhage	33	81	163	326	130	326	651	1302	260	651	1302	2605
<b>Total excess deaths</b>	<b>10455</b>	<b>26138</b>	<b>52275</b>	<b>104550</b>	<b>41820</b>	<b>104550</b>	<b>209101</b>	<b>418202</b>	<b>83640</b>	<b>209101</b>	<b>418202</b>	<b>836403</b>

B.

CVD Type	Population infection rate in the COVID-19 pandemic															
	1.2			1.5			2			3			Relative Risk			
	Total ~ 10471	Total ~ 26178	Total ~ 52356	Total ~ 104713	Total ~ 209426	Total ~ 418851	Total ~ 83702									
Heart failure	313	509	397	479	783	1272	992	1196	1567	2544	1964	2393	3134	5088	3967	4786
Atrial fibrillation	256	446	367	418	645	1116	917	1044	1291	2231	1835	2089	2862	4462	3670	4177
Stable angina	241	426	331	382	303	1085	828	954	1205	2129	1656	1908	2410	4259	3312	3816
Coronary heart disease	184	370	349	440	459	924	871	1100	918	1849	1743	2200	1836	3697	3486	4401
Stroke not otherwise specified	193	303	227	196	482	758	566	490	963	1516	1133	980	1927	3032	2266	1959
Myocardial infarction	172	253	197	235	429	633	494	589	858	1266	987	1177	1717	2532	1974	2354
Transient ischaemic attack	149	242	185	161	373	606	462	402	746	1211	924	803	1493	2422	1848	1606
Peripheral arterial disease	105	182	147	184	263	456	366	461	526	911	733	921	1053	1822	1465	1842
Unstable angina	41	87	84	125	102	218	211	311	203	436	421	623	407	871	842	1245
Ischaemic stroke	40	87	91	97	99	218	226	244	198	436	453	487	397	873	906	975
Deep vein thrombosis	47	84	64	88	118	209	159	220	237	419	318	440	474	838	637	880
Pulmonary embolism	23	44	39	57	58	111	97	142	116	222	193	284	232	444	386	568
Abdominal aortic aneurysm	26	50	42	42	64	124	104	105	129	248	209	209	258	497	418	419
Intracerebral haemorrhage	18	29	28	26	44	74	64	64	88	147	129	128	176	294	257	256
Cardiac arrest	6	13	12	13	15	34	30	33	29	67	60	65	59	135	119	131
Subarachnoid haemorrhage	7	10	10	5	18	26	24	14	36	52	48	27	72	106	96	55
<b>Total excess deaths</b>	<b>3137</b>	<b>2947</b>	<b>7843</b>	<b>7367</b>	<b>15685</b>	<b>14735</b>	<b>18224</b>	<b>25648</b>	<b>18224</b>	<b>31371</b>	<b>29470</b>	<b>7843</b>	<b>7367</b>	<b>15685</b>	<b>14735</b>	<b>18224</b>
Heart failure	1254	2035	1587	1914	3134	5088	3967	4786	6268	10176	7934	9572	12535	20352	15868	19143
Atrial fibrillation	1033	1785	1468	1671	2582	4462	3670	4177	5163	8924	7339	8354	10326	17848	14679	16708
Stable angina	964	1704	1325	1526	2410	4259	3312	3816	4820	8518	6623	7832	9641	17036	13247	15265
Coronary heart disease	735	1470	1394	1760	1836	3697	3486	4401	3073	7394	6971	8892	7346	14789	13942	17604
Stroke not otherwise specified	771	1213	908	784	1927	3032	2266	1959	3853	6063	4532	3918	7706	12127	9063	7837
Myocardial infarction	687	1013	790	942	1717	2532	1974	2354	3433	5064	3948	4708	6866	10128	7897	9417
Transient ischaemic attack	597	969	739	643	1493	2422	1848	1606	2985	4845	3696	3213	5971	9690	7391	6426
Peripheral arterial disease	421	729	586	737	1053	1822	1465	1842	2105	3645	2931	3694	4211	7289	5861	7368
Unstable angina	163	348	337	498	407	871	842	1245	813	1742	1685	2491	1627	3484	3369	4981
Ischaemic stroke	159	349	362	390	397	873	906	975	793	1745	1812	1950	1586	3490	3624	3899
Deep vein thrombosis	190	335	255	352	474	838	637	880	948	1675	1273	1760	1895	3351	2546	3519
Pulmonary embolism	93	178	155	227	232	444	386	568	464	888	773	1136	929	1777	1546	2271
Abdominal aortic aneurysm	103	199	167	168	258	497	418	419	516	994	836	838	1032	1988	1672	1675
Intracerebral haemorrhage	71	118	103	102	176	294	257	256	353	589	515	512	705	1177	1029	1025
Cardiac arrest	23	54	48	52	59	135	119	131	117	270	238	261	234	539	477	522
Subarachnoid haemorrhage	29	42	38	22	72	105	95	55	144	209	191	109	287	419	381	218
<b>Total excess deaths</b>	<b>12548</b>	<b>11788</b>	<b>9112</b>	<b>8370</b>	<b>18224</b>	<b>36448</b>	<b>51297</b>	<b>72896</b>	<b>102593</b>	<b>117878</b>	<b>102593</b>	<b>117878</b>	<b>102593</b>	<b>117878</b>	<b>102593</b>	<b>117878</b>
Heart failure	2507	4070	3174	3829	6268	10176	7934	9572	12535	20352	15868	19143	25070	40705	31736	38287
Atrial fibrillation	2065	3570	2936	3342	5163	8924	7339	8354	10326	17848	14679	16708	20653	35697	29358	33416
Stable angina	1928	3407	2649	3053	4820	8518	6623	7832	9641	17036	13247	15265	19281	34071	26494	30530
Coronary heart disease	1469	2958	2785	3521	3673	7394	6971	8892	7346	14788	13942	17604	14691	29577	27856	35208
Stroke not otherwise specified	1541	2425	1813	1567	3853	6063	4532	3918	7706	12127	9063	7837	15413	24254	18127	15674
Myocardial infarction	1373	2026	1579	1863	3433	5064	3948	4708	6866	10128	7897	9417	13732	20257	15793	18634
Transient ischaemic attack	1194	1938	1478	1285	2985	4845	3696	3213	5971	9690	7391	6426	11941	19379	14782	12851
Peripheral arterial disease	842	1458	1172	1474	2105	3645	2931	3694	4211	7289	5861	7368	8421	14579	11723	14736
Unstable angina	325	697	674	966	813	1742	1685	2491	1627	3484	3369	4981	3253	6968	6738	9662
Ischaemic stroke	317	698	725	780	793	1745	1812	1950	1586	3490	3624	3899	3172	6980	7248	7799
Deep vein thrombosis	379	670	509	704	948	1675	1273	1760	1895	3351	2546	3519	3790	6702	5092	7039
Pulmonary embolism	186	355	309	454	464	888	773	1136	929	1777	1546	2271	1857	3553	3092	4542
Abdominal aortic aneurysm	206	398	334	335	516	994	836	838	1032	1988	1672	1675	2063	3976	3344	3350
Intracerebral haemorrhage	141	235	206	205	353	589	515	512	705	1177	1029	1025	1410	2354	2059	2049
Cardiac arrest	47	106	96	104	117	270	238	261	234	539	477	522	468	1078	964	1044
Subarachnoid haemorrhage	57	84	78	44	144	209	191	109	287	419	381	218	575	838	763	436
<b>Total excess deaths</b>	<b>25987</b>	<b>20519</b>	<b>15788</b>	<b>14579</b>	<b>36448</b>	<b>72896</b>	<b>102593</b>	<b>117878</b>								
<b>Number of comorbidities</b>	<b>no</b>	<b>one</b>	<b>two</b>	<b>three+</b>	<b>no</b>	<b>one</b>	<b>two</b>	<b>three+</b>	<b>no</b>	<b>one</b>	<b>two</b>	<b>three+</b>	<b>no</b>	<b>one</b>	<b>two</b>	<b>three+</b>

Percentage change in activity compared with pre-COVID-19 levels (1 October 2019)



COVID-19 Cases	0	0	0	47	14380	80026	81589	0	0	0	47	14380	80026	81589	0	0	0	47	14380	80026	81589	0	0	0	2	1701	110574	0	0	0	0	2	36	29474	177474	0	0	0	0	2	36	29474
----------------	---	---	---	----	-------	-------	-------	---	---	---	----	-------	-------	-------	---	---	---	----	-------	-------	-------	---	---	---	---	------	--------	---	---	---	---	---	----	-------	--------	---	---	---	---	---	----	-------